A Study of Nivolumab and Hydroxychloroquine or Nivolumab/Ipilimumab and Hydroxychloroquine in Advanced Melanoma

This study will evaluate the safety, tolerability and efficacy (objective response rate) of using hydroxychloroquine (HCQ) in combination with nivolumab and ipilimumab or with nivolumab alone in subjects with advanced/metastatic melanoma.

Trial Details

NCT ID
NCT04464759
Phase
PHASE1 / PHASE2
Sponsor
Ravi Amaravadi, MD
Status
RECRUITING
Cancer Type
Melanoma
Interventions
  • Nivolumab
  • Hydroxychloroquine
  • Ipilimumab
Locations (sample)
  • Philadelphia, Pennsylvania, United States|39.95238,-75.16362

Key Eligibility Criteria

  • Histological or cytological evidence of melanoma, unresectable Stage III or Stage IV, any genotype, and any programmed death-ligand 1 (PD-L1) immun…
  • Phase 1a: nivolumab + HCQ: any prior treatment, or treatment naïve
  • Phase 2: nivolumab + HCQ:
  • \- - Cohort 2a: prior immunotherapy in the adjuvant or metastatic setting is required

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Melanoma Trials on Trialify →